Eli Lilly Halves €2.3B German Investment as Pharma Fights EU Drug Price Caps
LLY sits 80% above its 52-week low of $623.78.
Summary
Global pharmaceutical companies, including Eli Lilly and Pfizer, are actively pressuring European governments over proposed drug pricing legislation. Eli Lilly announced it will halve a planned €2.3 billion ($2.7 billion) investment in Germany, citing the proposed changes, while Pfizer warned the German chancellor that its investments are at risk. This reflects a broader industry strategy to influence policy by threatening to pull investment, following a similar situation in Britain. These actions highlight significant regulatory headwinds for major pharmaceutical companies in key European markets, directly impacting capital allocation and future growth potential. Germany's proposed law faces parliamentary debates over the coming months, which could lead to further changes.
At the time of this announcement, LLY was trading at $1,121.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.